Prolysis Ltd, a private company focused on the discovery and development of novel antibiotic therapies, has announced that it has appointed Bioscience Managers Limited (BML) as its corporate finance advisor for its Series B financing. BML will lead the marketing and closing of this venture round to assist Prolysis move its programs towards clinical development.